Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 232 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Enhanced Label Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04499963
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Theracurmin HP
Drug
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

NCT02526511
View directory record Official record
Conditions
Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Arterial Spin Labeling Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Perfusion Magnetic Resonance Imaging
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Active, not recruiting Phase 1 Interventional

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216
View directory record Official record
Conditions
Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
Interventions
[18F]FLT, PET/CT, ribociclib, paclitaxel
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

NCT01893190
View directory record Official record
Conditions
Ruptured Cerebral Aneurysm, Ruptured Berry Aneurysm
Interventions
Nimodipine, Nimodipine Microparticles
Drug
Lead sponsor
Edge Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TRUST Study of Adolescent Weight Self-Management

NCT03016247
View directory record Official record
Conditions
Adolescent Obesity
Interventions
TRUST Intervention, Enhanced Usual Care
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
10 Years to 12 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 28, 2026, 4:41 PM EDT
Withdrawn Phase 4 Interventional

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

NCT00037115
View directory record Official record
Conditions
Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions
interferon beta 1a, methotrexate, methylprednisolone
Drug
Lead sponsor
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 28, 2026, 4:41 PM EDT
Terminated Phase 4 Interventional Results available

Predictors of AAA Expansion and/or Rupture

NCT03231397
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA)
Interventions
Assess AAA rupture risk by PET-CTA scans, 18F-fludeoxyglucose (FDG), 11C-PBR28
Drug · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 28, 2026, 4:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CT Antigen TCR-Engineered T Cells for Myeloma

NCT01892293
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Treatment with NY-ESO-1c259-modified T cells
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Duarte, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

NCT02683824
View directory record Official record
Conditions
Healthy Subject, Pancreatic Carcinoma
Interventions
Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
Diagnostic Test · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma

NCT03922984
View directory record Official record
Conditions
Glioblastoma
Interventions
MRI with Arterial Spin Labeling (ASL)
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 28, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

NCT06566079
View directory record Official record
Conditions
Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Interventions
ISM6331
Drug
Lead sponsor
InSilico Medicine Hong Kong Limited
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Active, not recruiting No phase listed Interventional

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
3'-deoxy-3'-[18F]fluorothymidine
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Recruiting Phase 1 Interventional

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT03647358
View directory record Official record
Conditions
Thyroid Carcinoma, Metastatic Thyroid Carcinoma
Interventions
PET/CT Scan, Iodine-124
Device · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Veterans Walk for Health Study

NCT00123435
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Hyperlipidemia, Hypertension, Obesity
Interventions
Nutritional counseling, Walking program, Simple pedometer, Enhanced pedometer
Behavioral · Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older · Male only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 28, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction

NCT01440517
View directory record Official record
Conditions
Diabetes Mellitus, Heart Failure
Interventions
Tc99m-Maraciclatide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 28, 2026, 4:41 PM EDT
Completed No phase listed Observational

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

NCT04069299
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
68Ga-DOTATATE, Positron Emission Tomography (PET) Scan
Drug · Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Recruiting Phase 1 Interventional

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

NCT05618925
View directory record Official record
Conditions
Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions
N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newport Beach, California • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Recruiting Phase 1 Interventional

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

NCT02852213
View directory record Official record
Conditions
AADC Deficiency
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
24 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
3
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

Academic-Industrial Partnership for Translation of Acoustic Angiography

NCT03544268
View directory record Official record
Conditions
Signs and Symptoms
Interventions
Acoustic Angiography, Definity
Device · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 28, 2026, 4:41 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151
View directory record Official record
Conditions
Colon Cancer
Interventions
Pembrolizumab, Porustobart
Drug
Lead sponsor
Solstice Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Improving Prescription Drug Warning Labels

NCT00846209
View directory record Official record
Conditions
Enhanced Text, Enhanced Text + Icon
Interventions
Enhanced drug labeling
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients

NCT01092754
View directory record Official record
Conditions
Pathological Processes
Interventions
MRI, Gadoversetamide
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
2 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
12
States / cities
Little Rock, Arkansas • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer

NCT00804245
View directory record Official record
Conditions
Prostate Cancer
Interventions
needle biopsy, PET-CT scans supplemented with 11C-Choline tracer
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 28, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

NCT00446836
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Paclitaxel polyglumex (Xyotax)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 28, 2026, 4:41 PM EDT